Table 1 Comparison of prognostic factors among survival cohorts

Gender

0

 Male

18

(64.3)

31

(63.3)

13

(48.1)

34

(53.1)

256

(52.2)

 Female

10

(35.7)

18

(36.7)

14

(51.9)

30

(46.9)

234

(47.8)

Age

0

 < 70

5

(17.9)

17

(34.7)

11

(40.7)

31

(48.4)

280

(57.1)

 ≥ 70

23

(82.1)

32

(65.3)

16

(59.3)

33

(51.6)

210

(42.9

BMI

1.1

 1 (< 18.5)

1

(3.7)

1

(2.0)

1

(3.7)

0

(0.0)

15

(3.1)

 2 (18.5–24.9)

10

(37.0)

22

(44.9)

10

(37.)

20

(32.3)

181

(37.3)

 3 (≥ 25.0)

16

(59.3)

26

(53.1)

16

(59.3)

42

(67.7)

289

(59.6)

Sarcopenia

18.8

 No

7

(31.8)

15

(41.7)

10

(47.6)

23

(50.0)

211

(51.8)

 Yes

15

(68.2)

21

(58.3)

11

(52.4)

23

(50.0)

196

(48.2)

Low muscle density

19.6

 No

5

(23.8)

11

(40.6)

6

(28.6)

13

(29.5)

159

(39.4)

 Yes

17

(76.2)

25

(69.4)

15

(71.4)

31

(70.5)

245

(60.6)

Sarcopenia + obese

0

 No

26

(92.9)

44

(89.8)

26

(96.3)

63

(98.4)

465

(94.9)

 Yes

2

(7.1)

5

(10.2)

1

(3.7)

1

(1.6)

25

(5.1)

Diabetes mellitus

0.1

 No

22

(78.6)

41

(83.7)

20

(76.9)

48

(75.0)

402

(82.0)

 Yes

6

(21.4)

8

(16.3)

6

(23.1)

16

(25.0)

88

(18.0)

Congestive heart failure

0

 No

25

(89.3)

45

(91.8)

24

(88.9)

63

(98.3)

466

(95.1)

 Yes

3

(10.7)

4

(8.2)

3

(11.1)

1

(1.6)

24

(4.9)

COPD

0

 No

27

(96.4)

44

(89.8)

23

(85.2)

62

(96.9)

454

(92.7)

 Yes

1

(3.6)

5

(10.2)

4

(14.8)

2

(3.1)

26

(7.3)

Charlson comorbidity index

0.4

 0

11

(39.3)

23

(46.9)

10

(38.5)

39

(60.9)

266

(54.4)

 1+

17

(60.7)

26

(53.1)

16

(61.5)

25

(39.1)

223

(45.6)

ASA score

 I–II

22

(78.6)

45

(91.8)

20

(74.1)

54

(85.7)

409

(84.2)

 III–IV

6

(21.4)

4

(8.2)

7

(25.9)

9

(14.3)

77

(15.8)

CEA

8.6

 < 7 μg/L

21

(90.8)

28

(59.6)

11

(45.8)

36

(62.1)

360

(79.5)

 ≥ 7 μg/L

5

(19.2)

19

(40.4)

13

(54.2)

22

(37.9)

93

(20.5)

Tumor location

 Colon

20

(71.4)

31

(63.3)

14

(51.9)

41

(64.1)

371

(75.7)

0

 Rectum

8

(28.6)

18

(36.7)

13

(48.1)

23

(35.9)

119

(24.3)

T-stage

0

 1

2

(7.1)

0

1

(3.7)

2

(3.1)

34

(6.9)

 2

7

(25)

5

(10.2)

7

(25.9)

22

(34.3)

171

(34.9)

 3

16

(57.1)

38

(77.6)

17

(63)

36

(56.2)

270

(55.1)

 4

3

(10.7)

6

(12.2)

2

(7.4)

4

(6.2)

15

(3.1)

N-stage

0

 0

8

(28.6)

13

(26.5)

6

(22.2)

36

(56.2)

303

(61.8)

 1

5

(17.9)

10

(20.4)

7

(25.9)

11

(17.2)

103

(21)

 2

12

(42.9)

21

(42.9)

7

(25.9)

7

(25.9)

33

(6.7)

X

3

(10.7)

5

(10.4)

7

(25.9)

10

(15.6)

51

(10.4)

Tumor stage

0

 I

7

(25.0)

4

(8.2)

5

(18.5)

22

(34.4)

164

(33.5)

 II

4

(14.3)

14

(28.6)

8

(29.6)

24

(37.5)

190

(38.8)

 III

17

(60.7)

31

(63.3)

14

(51.9)

18

(28.1)

136

(27.8)

Tumor grade

1.5

 Good

1

(3.7)

5

(10.4)

3

(11.1)

10

(15.9)

66

(13.7)

 Moderate

16

(59.3)

36

(75.0)

21

(77.8)

47

(74.6)

377

(78.1)

 Poor

8

(29.6)

7

(14.6)

3

(11.1)

5

(7.9)

33

(6.8)

 Unknown/other

2

(7.4)

0

0

1

(1.6)

7

(1.4)

Radicality

0.3

 R0

26

(92.6)

48

(98.0)

27

(100.0)

63

(98.4)

477

(97.5)

 R1

2

(7.1)

1

(2.0)

0

1

(1.6)

12

(2.5)

Postoperative complications

0

 No

6

(21.4)

24

(49.0)

8

(29.6)

38

(59.4)

298

(60.8)

 Yes

22

(78.6)

25

(51.)

19

(70.4)

26

(40.6)

193

(39.2)

Readmission < 30 days

0.1

 No

24

(88.9)

47

(95.9)

23

(85.2)

55

(85.9)

438

(89.4)

 Yes

3

(11.1)

2

(4.1)

4

(14.8)

9

(14.1)

52

(10.6)

Neoadjuvant chemotherapy

0

 No

20

(71.4)

33

(59.3)

16

(59.3)

43

(67.2)

383

(78.3)

 Yes

8

(28.6)

16

(32.7)

11

(40.7)

21

(32.8)

106

(21.7)

Adjuvant chemotherapy

0

 No

28

(100)

37

(77.1)

22

(81.5)

55

(85.9)

382

(78.6)

 Yes

0

11

(22.9)

5

(18.5)

9

(14.1)

104

(21.4)